Park Su Hyeong, Woo Hye Seung, Hong In Kyung, Park Eun Jung
Department of Hepatobiliary and Pancreatic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Division of Colon and Rectal Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Cancers (Basel). 2023 Oct 22;15(20):5098. doi: 10.3390/cancers15205098.
The Naples prognostic score (NPS) is a scoring system that reflects a patient's systemic inflammatory and nutritional status. This study aimed to evaluate whether postoperative NPS is effective in assessing the prognosis of stage II-III colorectal cancer (CRC) patients compared with preoperative NPS.
Between 2005 and 2012, a total of 164 patients diagnosed with stage II-III CRC, who underwent curative resection followed by adjuvant chemotherapy, were divided into two groups: Group 0-1 (NPS = 0-2) and Group 2 (NPS = 3 or 4). Preoperative NPS was calculated based on the results before surgeries, and postoperative NPS was assessed using the results obtained before adjuvant chemotherapy.
The overall survival of Group 0-1 was higher than that of Group 2 in both pre- and postoperative NPS assessments. According to the ROC curve analysis, the Area Under the Curve (AUC) ratio for postoperative NPS was 0.64, compared with 0.57 for preoperative NPS, 0.52 for the preoperative neutrophil-lymphocyte ratio ( = 0.032), and 0.51 for the preoperative platelet-lymphocyte ratio ( = 0.027).
Postoperative NPS is effective in predicting the prognosis of stage II-III CRC patients who underwent curative resection followed by adjuvant chemotherapy. The use of NPS could be beneficial in evaluating the prognosis of CRC patients after surgeries.
那不勒斯预后评分(NPS)是一种反映患者全身炎症和营养状况的评分系统。本研究旨在评估与术前NPS相比,术后NPS在评估II-III期结直肠癌(CRC)患者预后方面是否有效。
在2005年至2012年期间,共有164例诊断为II-III期CRC且接受了根治性切除并辅助化疗的患者被分为两组:0-1组(NPS = 0-2)和2组(NPS = 3或4)。术前NPS根据手术前的结果计算,术后NPS使用辅助化疗前获得的结果进行评估。
在术前和术后NPS评估中,0-1组的总生存率均高于2组。根据ROC曲线分析,术后NPS的曲线下面积(AUC)比值为0.64,术前NPS为0.57,术前中性粒细胞与淋巴细胞比值为0.52(P = 0.032),术前血小板与淋巴细胞比值为0.51(P = 0.027)。
术后NPS可有效预测接受根治性切除并辅助化疗的II-III期CRC患者的预后。使用NPS可能有助于评估CRC患者术后的预后。